Frazier & Deeter
US accountancy firm with a UK life sciences advisory practice, based in Cambridge and London.
On 10 September 2026, Frazier & Deeter co-published a report with the BioIndustry Association finding that ten deals took 75.2% of the £2.83 billion raised by UK life sciences in H1 2026.
Last refreshed: 22 September 2026 · Appears in 1 active topic
Timeline for Frazier & Deeter
Co-published the life-sciences capital concentration report
UK Startups and Innovation: Ten raises took 75.2% of life sciencesBackground
Frazier & Deeter UK operates as the British Arm of Frazier & Deeter, an accounting and advisory firm founded in Atlanta, Georgia and now one of the larger US accounting practices. The UK Arm serves mid-market biotech and life sciences companies from offices in London and Cambridge.
It relocated to Cambridge's St John's Innovation Centre in January 2025 and has won industry recognition including Best Biotech Financial Services Firm in the International Life Sciences Awards, reflecting a practice built specifically around the sector's tax and advisory needs.
Its tax and audit work concentrates on UK R&D tax relief and Patent Box claims, advisory areas that matter most to companies scaling from UK research toward the US market, the same corridor its Atlanta-founded parent already spans.
Frazier & Deeter co-authors funding report
Frazier & Deeter UK, the British Arm of the Atlanta-founded accounting firm, produced the concentration finding with the BioIndustry Association from its Cambridge and London offices, work that sits alongside its core practice advising mid-market biotech clients on R&D tax relief and Patent Box claims . The firm opened its first UK office in 2019 and grew through the 2021 acquisition of Cambridge-based Confluence Tax.
Publishing sector-wide funding data sits outside a typical accountancy brief, but fits a firm whose client base concentrates in the same life sciences companies the report covers, giving it a direct commercial reason to track where the money goes.
